A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy

Preclinical studies note that a major cannabinoid receptor, CB1, is expressed in pain modulating regions, suggesting that cannabinoids binding to the CB1 receptor may modulate nociceptive transmission.13 The majority of work in this area has focused on the partial CB1 agonist delta-9-tetrahydrocannabinol (THC). Indeed, there is recent evidence showing nociceptive benefits of inhaled cannabis containing THC as low as 1.3% [26, but other work suggests analgesia occurs only with higher potencies (eg, 9.4%;21).

from The Journal of Pain https://ift.tt/2Ck9zGZ
via IFTTT